← All trials
NCT05695287
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 22, 2021
- Primary completion
- Nov 19, 2022
- Completion date
- Dec 16, 2022
- First posted
- Jan 25, 2023
- Last posted
- Jan 25, 2023
- Enrollment
- 89
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Astana Medical UniversityLead sponsor
- Astana Medical UniversityReponsible party - principal investigator
- Astana Medical UniversityStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.